L1CAM expression in colorectal cancer identifies a high-risk group of patients with dismal prognosis already in early-stage disease

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–1502.
   PubMed Web of Science ®Google Scholar
• Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog. 2013;18(1–2):43–73.
   PubMedGoogle Scholar
• Guyot F, Faivre J, Manfredi S, et al. Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol. 2005;16(5):756–761.
   PubMed Web of Science ®Google Scholar
• van Gestel YR, de Hingh IH, van Herk-Sukel MP, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol. 2014;38(4):448–454.
   PubMed Web of Science ®Google Scholar
• Oskarsson T, Batlle E, Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell. 2014;14(3):306–321.
   PubMed Web of Science ®Google Scholar
• Janni W, Vogl FD, Wiedswang G, et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse–a European pooled analysis. Clin Cancer Res. 2011;17(9):2967–2976.
   PubMed Web of Science ®Google Scholar
• Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353(8):793–802.
   PubMed Web of Science ®Google Scholar
• Altevogt P, Doberstein K, Fogel M. L1CAM in human cancer. Int J Cancer. 2016;138(7):1565–1576.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol. 2005;2(8):416–422.
   PubMedGoogle Scholar
• Gavert N, Sheffer M, Raveh S, et al. Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res. 2007;67(16):7703–7712.
   PubMed Web of Science ®Google Scholar
• Gavert N, Conacci-Sorrell M, Gast D, et al. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol. 2005;168(4):633–642.
   PubMed Web of Science ®Google Scholar
• Gavert N, Vivanti A, Hazin J, et al. L1-mediated colon cancer cell metastasis does not require changes in EMT and cancer stem cell markers. Mol Cancer Res. 2011;9(1):14–24.
   PubMed Web of Science ®Google Scholar
• Gavert N, Ben-Shmuel A, Lemmon V, et al. Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J Cell Sci. 2010;123(12):2135–2143.
   PubMed Web of Science ®Google Scholar
• Er EE, Valiente M, Ganesh K, et al. Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization. Nat Cell Biol. 2018;20(8):966–978.
   PubMed Web of Science ®Google Scholar
• Obenauf AC, Massague J. Surviving at a distance: organ specific metastasis. Trends Cancer. 2015;1(1):76–91.
   PubMed Web of Science ®Google Scholar
• Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014;505(7483):327–334.
   PubMed Web of Science ®Google Scholar
• Rafii S, Butler JM, Ding BS. Angiocrine functions of organ-specific endothelial cells. Nature. 2016;529(7586):316–325.
   PubMed Web of Science ®Google Scholar
• Malladi S, Macalinao DG, Jin X, et al. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell. 2016;165(1):45–60.
   PubMed Web of Science ®Google Scholar
• Ghajar CM, Peinado H, Mori H, et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 2013;15(7):807–817.
   PubMed Web of Science ®Google Scholar
• Valiente M, Obenauf AC, Jin X, et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 2014;156(5):1002–1016.
   PubMed Web of Science ®Google Scholar
• Boland CR, Goel A. Prognostic subgroups among patients with stage II colon cancer. N Engl J Med. 2016;374(3):277–278.
   PubMed Web of Science ®Google Scholar
• Marshall JL. Risk assessment in Stage II colorectal cancer. Oncology (Williston Park). 2010;24(1 Suppl 1):9–13.
   PubMed Web of Science ®Google Scholar
• Benson AB, 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408–3419.
   PubMed Web of Science ®Google Scholar
• Gast D, Riedle S, Issa Y, et al. The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene. 2008;27(9):1281–1289.
   PubMed Web of Science ®Google Scholar
• Arlt MJ, Novak-Hofer I, Gast D, et al. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res. 2006;66(2):936–943.
   PubMed Web of Science ®Google Scholar
• Wolterink S, Moldenhauer G, Fogel M, et al. Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma. Cancer Res. 2010;70(6):2504–2515.
   PubMed Web of Science ®Google Scholar
• Schafer H, Dieckmann C, Korniienko O, et al. Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. Cancer Lett. 2012;319:66–82.
   PubMed Web of Science ®Google Scholar